Vesper Bio doses first volunteer in Phase I study of first-in-class oral treatment for Frontotemporal Dementia (FTD)
- Vesper Bio, backed by Lundbeckfonden BioCapital, initiates a Phase I study to evaluate its lead asset VES001, for the treatment of FTD (GRN mutation), addressing a critical unmet medical need
- VES001 is a product designed with the needs of the patients and their care givers in mind
- The Phase I study will assess safety, tolerability and pharmacokinetics and target engagement biomarkers across a range of single and multiple doses, moving on to a Phase Ib/c Proof of Concept
Copenhagen, Denmark, 7th December 2023 – Vesper Bio ApS (“Vesper” or “the Company”), a clinical stage biotech and world leader in sortilin receptor biology, today announces that the first volunteer has been dosed with its lead compound VES001, a patient friendly, first-in-class, brain penetrant, oral treatment, that could bring a meaningful disease-modifying benefit to patients suffering from Frontotemporal Dementia harbouring loss of function mutations in the progranulin gene (FTD)(GRN). VES001 aims to rebalance circulating progranulin in life changing diseases.
